The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
Therapeutics Development Initiative, 2012IMD-026259 - An Innovative Drug for Disease-Modifying Treatment of Parkinson´s DiseaseObjective/Rationale: 
 IMD-026259 represents a proprietary highly potent and selective small molecule inhibitor of NF-kB pathway and 1 alpha (HIF-1alpha) mediated transcriptional activity. Comprehensive...
- 
      
  
MJFF Research Grant, 2012Gremlin-1, a Putative VTA-derived Neuroprotective Factor in Parkinson's Disease (Supplement)Promising Outcomes of Original Grant: 
 We have previously postulated that the glycoprotein Gremlin has a neuroprotective role in PD. To test this hypothesis, we sought to develop a gremlin knockout pre...
- 
      
  
Target Validation, 2012Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson’s DiseaseObjective/Rationale: 
 Mitochondria are the major energy generators of a cell. Dysfunctional mitochondria are central to the pathology of Parkinson’s Disease (PD). We hypothesize that improving the...
- 
      
  
Biomarker Development, 2012Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson’s Disease.Objective/Rationale: 
 Parkinson’s disease is associated with the appearance of large, intracellular aggregates termed Lewy bodies consisting of damaged, truncated, aggregated and misfolded proteins...
- 
      
  
Target Validation, 2012Antiparkinsonian Effects of T-type Calcium Channel InhibitorsObjective/Rationale: 
 Parkinson’s disease is associated with changes in the electrical activity of nerve cells in the basal ganglia and thalamus, including the emergence of abnormal burst discharges...
- 
      
  
Rapid Response Innovation Awards, 2012A Genetic Strategy to Restore Impaired Noradrenergic Function by Increasing Expression of Noradrenergic Phenotypes in the Locus Coeruleus in Parkinson’s Disease Pre-clinical ModelsObjective/Rationale: 
 Compelling evidence demonstrated that a dysfunction of the locus coeruleus (LC)-
 noradrenaline (NE) system in the brain not only contributes to alterations in
 cognitive and motor...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.